Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Q/C Technologies, Inc. (QCLS)November 14, 2025, the executive acquired 11,420 shares of common stock at a reported price of $0 through a grant of restricted stock units (RSUs). These RSUs were originally granted on October 3, 2025, but were subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan, which stockholders approved on November 14, 2025, causing the RSUs to vest immediately upon issuance. Following this transaction, the reporting person directly beneficially owns 12,500 shares of Q/C Technologies common stock.
Q/C Technologies, Inc. (QCLS) filed a Notification of Late Filing on Form 12b-25 for its Form 10-Q covering the nine months ended September 30, 2025. The company says it needs additional time to complete and finalize the financial statements required for the report.
Q/C Technologies anticipates filing the Form 10-Q on or before the fifth calendar day following the prescribed due date under Rule 12b-25.
Q/C Technologies, Inc. reported that stockholders reconvened on November 14, 2025 and approved a second amendment to the 2021 Equity Incentive Plan, increasing the shares available for awards by 1,375,000 to a new total of 1,400,000 common shares.
All proposals presented at the special meeting were approved. As context, holders with an aggregate of 1,129,053 votes were present in person or by proxy. On the record date of September 18, 2025, there were 2,052,974 common shares outstanding and multiple series of preferred stock outstanding with voting rights as limited by their certificates of designations. The company filed the plan amendment as Exhibit 10.1.
Q/C Technologies filed a definitive proxy for a virtual special meeting on November 10, 2025. Stockholders are asked to approve several capital actions the Board recommends “FOR,” including an issuance authorization under Nasdaq Listing Rule 5635(d), an equity plan increase, a potential reverse split, and a meeting adjournment right.
The Issuance Proposal seeks approval to issue common stock in an amount equal to or in excess of 20% of pre-transaction shares, covering shares underlying Series H and Series I preferred and multiple warrant grants, plus advisory and milestone securities. Following a 1‑for‑100 reverse split, Series H terms adjusted to a conversion price of $3.3713, with up to 2,076,351 Series H conversion shares and 2,076,351 investor warrants at $3.3713.
The plan amendment would add 1,375,000 shares, taking the 2021 Equity Incentive Plan to 1,400,000 shares. The Reverse Stock Split Proposal authorizes a Board‑selected ratio from 1‑for‑2 to 1‑for‑250. The Adjournment Proposal allows additional solicitation if needed. Common shares outstanding were 2,052,974 as of September 18, 2025; this is a baseline figure, not the amount being offered.
TNF Pharmaceuticals, Inc. (TNFA) is asking shareholders to approve two governance changes. First, a proposal would amend the Certificate of Incorporation to permit the Board, within
Bruce Bernstein, a director, filed an Initial Statement of Beneficial Ownership reporting an indirect interest in Q/C Technologies, Inc. (QCLS). The form states a beneficial interest in 23 common shares held indirectly through Stormy Monday LLC. It also reports warrants dated 11/17/2020 that expire 05/18/2026 covering 23 underlying common shares with a listed exercise price of
Joshua Silverman, Executive Chairman and Director, reported the immediate grant and vesting of 8,644 Restricted Stock Units (RSUs) on
Q/C Technologies (QCLS) reported an insider equity award. Director Stephen Friscia acquired 2,161 shares of common stock on October 3, 2025, coded as an acquisition at $0 per share. The filing notes the shares arose from a grant of restricted stock units (RSUs) that vested immediately upon grant.
Following this transaction, Friscia’s beneficial ownership stands at 2,161 shares, held directly.
Q/C Technologies (QCLS) reported an insider equity grant. Director and Chief Medical Officer Mitchell Glass acquired 1,080 shares of common stock on October 3, 2025 via a grant of restricted stock units that vested immediately.
The filing lists the transaction price as $0, consistent with an RSU award, and shows 1,080 shares beneficially owned directly following the transaction.
Form 4 shows Billy Joe White, a director of Q/C Technologies, Inc. (ticker QCLS), received a grant of 2,161 Restricted Stock Units (RSUs) that vested immediately on
This filing records an equity compensation event for an insider rather than an open-market purchase or sale; the immediate vesting increases the director’s direct stake by the stated share count and is reportable under Section 16(a).